+

WO1999033453A3 - R-procyclidine utilisee dans le traitement de l'incontinence urinaire - Google Patents

R-procyclidine utilisee dans le traitement de l'incontinence urinaire Download PDF

Info

Publication number
WO1999033453A3
WO1999033453A3 PCT/US1998/027704 US9827704W WO9933453A3 WO 1999033453 A3 WO1999033453 A3 WO 1999033453A3 US 9827704 W US9827704 W US 9827704W WO 9933453 A3 WO9933453 A3 WO 9933453A3
Authority
WO
WIPO (PCT)
Prior art keywords
procyclidine
urinary incontinence
enantiomerically enriched
treating urinary
pharmaceutically acceptable
Prior art date
Application number
PCT/US1998/027704
Other languages
English (en)
Other versions
WO1999033453A2 (fr
Inventor
Vincent L Fabiano
John R Mccullough
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Priority to EP98964970A priority Critical patent/EP1043992A2/fr
Priority to AU20179/99A priority patent/AU2017999A/en
Priority to CA002315840A priority patent/CA2315840A1/fr
Priority to JP2000526210A priority patent/JP2001527038A/ja
Publication of WO1999033453A2 publication Critical patent/WO1999033453A2/fr
Publication of WO1999033453A3 publication Critical patent/WO1999033453A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur un procédé de traitement de l'incontinence urinaire telle que l'incontinence due à l'instabilité du muscle vésical de la vessie et utilisant (R)-procyclidine enrichie de façon énantiomère. Ce procédé consiste à administrer une quantité thérapeutiquement efficace de (R)-procyclidine enrichie de façon énantiomère, ou un sel pharmaceutiquement acceptable de celle-ci, pratiquement exempt de énantiomère (S)-procyclidine. L'invention porte également sur des compositions pharmaceutiques utilisées dans le traitement de l'incontinence urinaire et comprenant (R)-procyclidine enrichie de façon énantiomère, ou un sel pharmaceutiquement acceptable de celle-ci et un excipient acceptable.
PCT/US1998/027704 1997-12-31 1998-12-29 R-procyclidine utilisee dans le traitement de l'incontinence urinaire WO1999033453A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP98964970A EP1043992A2 (fr) 1997-12-31 1998-12-29 $i(R)-PROCYCLIDINE UTILISEE DANS LE TRAITEMENT DE L'INCONTINENCE URINAIRE
AU20179/99A AU2017999A (en) 1997-12-31 1998-12-29 (r)-procyclidine for treating urinary incontinence
CA002315840A CA2315840A1 (fr) 1997-12-31 1998-12-29 R-procyclidine utilisee dans le traitement de l'incontinence urinaire
JP2000526210A JP2001527038A (ja) 1997-12-31 1998-12-29 尿失禁を治療するためのｒ−プロサイクリディン

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7027397P 1997-12-31 1997-12-31
US60/070,273 1997-12-31

Publications (2)

Publication Number Publication Date
WO1999033453A2 WO1999033453A2 (fr) 1999-07-08
WO1999033453A3 true WO1999033453A3 (fr) 1999-10-07

Family

ID=22094274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/027704 WO1999033453A2 (fr) 1997-12-31 1998-12-29 R-procyclidine utilisee dans le traitement de l'incontinence urinaire

Country Status (5)

Country Link
EP (1) EP1043992A2 (fr)
JP (1) JP2001527038A (fr)
AU (1) AU2017999A (fr)
CA (1) CA2315840A1 (fr)
WO (1) WO1999033453A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031208A2 (fr) * 1995-04-05 1996-10-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Utilisation de composes de piperidine ou de pyrrolidine substitues pour le traitement de maladies modulees par un recepteur sigma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031208A2 (fr) * 1995-04-05 1996-10-10 Byk Gulden Lomberg Chemische Fabrik Gmbh Utilisation de composes de piperidine ou de pyrrolidine substitues pour le traitement de maladies modulees par un recepteur sigma

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ALBERTS P: "CLASSIFICATION OF THE PRESYNAPTIC MUSCARINIC RECEPTOR SUBTYPE THAT REGULATES 3H-ACETHYLCHOLINE SECRETION IN THE GUINEA PIG URINARY BLADDER IN VITRO", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 274, no. 1, 1 July 1995 (1995-07-01), pages 458 - 468, XP000572112 *
ARIENS E J: "STEREOSELECTIVITY IN PHARMACODYNAMICS AND PHARMACOKINETICS", SCHWEIZ.MED.WSCHR, vol. 120, no. 5, 3 February 1990 (1990-02-03), pages 131 - 134, XP002051314 *
BARLOW, R. B. ET AL: "A comparison of stereospecificity at central and peripheral 'muscarine-sensitive' acetylcholine receptors: observations with the enantiomeric forms of procyclidine and tricyclamol", BR. J. PHARMACOL. (1981), 72(2), 277-80 CODEN: BJPCBM;ISSN: 0007-1188, XP002107613 *
BARLOW, RICHARD B.: "Differences in the stereospecificity of closely related compounds;a reinvestigation of the enantiomers of procyclidine, benzhexol, and their metho- and etho-salts", J. PHARM., PHARMACOL. (1971), 23(2), 90-7 CODEN: JPPMAB, XP002107611 *
JUNEMANN ET AL.: "Blasenfunktionsstörungen bei Parkinson-Syndrom", UROLOGY - AUSGABE A, vol. 29, no. 4, 1990, pages 170 - 175, XP002107614 *
MAGALI WAELBROCCK ET AL: "Stereoselective interaction of procyclidine, hexahydro-difenidol,hexbutinol and oxyphencyclimine, and of related antagonists, with four muscarinic receptors", EUROPEAN JOURNAL OF PHARMACOLOGY. MOLECULAR PHARMACOLOGY SECTION, vol. 227, no. 1, 1992, pages 33 - 42 42, XP002103656 *
MURPHY L.J.T.: "Urological problems in aged patients", AUSTRALIAN FAMILY PHYSICIAN, vol. 6, no. 1, 1977, pages 17 - 28, XP002107615 *
NORONHA-BLOB L ET AL: "ENANTIOMERS OF OXYBUTYNIN: IN VITRO PHARMACOLOGICAL CHARACTERIZATION AT M1, M2 AND M3 MUSCARINIC RECEPTORS AND IN VIVO EFFECTS ON URINARY BLADDER CONTRACTION, MYDRIASIS AND SALIVARY SECRETION IN GUINEA PIGS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 256, no. 2, 1 February 1991 (1991-02-01), pages 562 - 567, XP000572006 *
WAELBROECK M ET AL: "STEREOSELECTIVITY OF PROCYCLIDINE BINDING TO MUSCARINIC RECEPTOR SUBTYPES M-1 M-2 AND M-4.", EUR J PHARMACOL MOL PHARMACOL SECT, (1990) 3 (2-3), 135-142. CODEN: EJPPET. ISSN: 0922-4106., XP002107612 *
WAELBROECK, M. ET AL: "Thermodynamics of antagonist binding to rat muscarinic M2 receptors: Antimuscarinics of the pridinol, sila-pridinol, diphenidol and sila-diphenidol type", BR. J. PHARMACOL. (1993), 109(2), 360-70 CODEN: BJPCBM;ISSN: 0007-1188, XP002107610 *

Also Published As

Publication number Publication date
AU2017999A (en) 1999-07-19
WO1999033453A2 (fr) 1999-07-08
EP1043992A2 (fr) 2000-10-18
JP2001527038A (ja) 2001-12-25
CA2315840A1 (fr) 1999-07-08

Similar Documents

Publication Publication Date Title
CA2211400A1 (fr) Traitement de l'incontinence urinaire par la (s)-oxybutynine et la (s)-desethyloxybutynine
CA2257121A1 (fr) Methodes et compositions pour le traitement de l'incontinence urinaire utilisant (s)-oxybutynine
WO1996028148A3 (fr) Emploi d'un anti-inflammatoire non steroidien r dans une composition protectrice pour le traitement du cancer colorectal
HK1029916A1 (en) Use of inosine for the manufacture of a medicamentfor stimulating axonal outgrowth of central nervous system neurons.
WO1999022721A3 (fr) Procede de traitement de l'hypercholesterolemie a l'aide de polydiallylamine non substituee
WO1998029110A3 (fr) Preparation et methode de traitement de neoplasmes par inhalation
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
HU9303748D0 (en) Composition of l-dopa-esters
WO2000054756A3 (fr) Esters de nitrate et leur utilisation dans le traitement d'etats neurologiques
MY119375A (en) Treatment of tinnitus using neuroprotective agents
WO1999033450A3 (fr) Agents therapeutiques
WO2001024783A3 (fr) Utilisation de (+)-tramadol, de o-demethyltramadol ou de (+)-o-demethyltramadol, de o-desmethyle-n-mono-desmethyl-tramadol ou de (+)o-desmethyl-n-mono-desmethyl-tramadol pour traiter l'incontinence urinaire
WO1999022722A3 (fr) Utilisation de macrolides pour le traitement du cancer et de la degenerescence maculaire
AU693833B2 (en) Products containing G-CSF and TNF binding protein
CA2283255A1 (fr) Utilisation d'enantiomeres r d'anti-inflammatoires non steroidiens pour la prevention de la maladie d'alzheimer
EP1561462A3 (fr) Compositions pour traiter l'arythmie et procédés de traitement
EP0909172A4 (fr) PROCEDES ET COMPOSITIONS POUR TRAITER L'INCONTINENCE URINAIRE AVEC DU (R,s)-GLYCOPYRROLATE ENRICHI EN ENANTIOMERES
MY122052A (en) Method of treating tourette''s syndrome
WO1999033454A3 (fr) Procyclidine-s aux fins du traitement de l'incontinence urinaire
EP0909163A4 (fr) Procedes et compositions de traitement de l'incontinence urinaire a l'aide de (s,r)-glycopyrrolate enrichi en enantiomeres
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
WO2003002059A3 (fr) Metabolites de tolterodine
WO1999033453A3 (fr) R-procyclidine utilisee dans le traitement de l'incontinence urinaire
WO2001000187A3 (fr) Agents therapeutiques
EP0743068A3 (fr) Composition pour inhiber la perte osseuse contentant du sulfate de vanadium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2315840

Country of ref document: CA

Ref country code: CA

Ref document number: 2315840

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 526210

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 20179/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998964970

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998964970

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998964970

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载